PharmaMar announces the start of a pivotal study with plitidepsin in T-cell lymphoma
(Pharmamar) The primary endpoint is to analyze the efficacy of plitidepsin in the type of hematological cancer, angioimmunoblastic T-cell lymphoma, which is classified as a rare disease.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Hematology | Lymphoma | Rare Diseases | Study | T-cell Lymphoma